Home
overview
Arthritis is the leading cause of disability and is on a steady rise. There is currently no cure for arthritis. Emerging therapies are revealing more about the role of cytokines and other factors in arthritis. Biotech and pharmaceutical companies are developing new drug candidates that focus on targets such as cytokines and other immune response cells. There is a new understanding of how early and aggressive treatment can affect patient outcomes.

As a senior industry executive, you will be aware of the importance and potential of this field. We would therefore like to invite you to register for Advances in Anti Arthritic Agents. As you will see from the brochure, key speakers include representatives from leading international pharmaceutical and biotechnology companies.

The conference offers you the opportunity to network with key industry experts. Attend to discover the potential and realities of the anti arthritic market.

Companies attending SMi pharmaceutical events include:

3M Healthcare Pharmaceuticals - Abbott Laboratories - Amgen - AstraZeneca - Baxter Healthcare - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eli Lilly - Glaxo Wellcome - Hoffmann-La Roche - Janssen-Cilag - Johnson and Johnson - Knoll AG - Lederle - Merck Sharp and Dohme - Novartis - Novo Nordisk Pharmaceuticals - Parke-Davis - Pasteur Merieux MSD Ltd - Pharmacia and Upjohn - Pfizer Corporation - RhÔne-Poulenc Rorer - Proctor and Gamble - Schering-Plough - Smith and Nephew - SmithKline Beecham - Synthelabo - Warner Lambert - Wyeth Ayerst

Conference programme

9:00 Chairman's Opening Remarks

Prof Howard Bird

Prof Howard Bird, Consultant Rheumatologist, University of Leeds/Chapel Allerton Hospital

9:10 ADDRESSING THE PROBLEM OF ARTHRITIC DISORDERS

F Roy Jones, Director, Training and Development Service

F Roy Jones, Director, Training and Development Service, Jean Thompson, Consultant Trainer, Arthritis Care

  • Why arthritis is a major public health concern
  • Medicines and psychosocial interventions
  • Coventry University’s NHS R&D funded research
  • Expert patients
  • The place of medicines
  • Empowered patients in health care provision
  • 10:20 CONTROLLING THE SYMPTOMS AND PROGRESSION OF ARTHRITIS

    Dr Dajana Cesic

    Dr Dajana Cesic, Senior Medical Adviser, Hoechst Marion Roussel

  • Improving signs and symptoms and slowing the progression of RA
  • Affecting a unique stage in the disease process
  • Developing Arava
  • Mechanism of action of Arava
  • Pharmacoeconomical implications of DMARDs
  • Anticipating the future of DMARDs
  • 10:20 MATRIX METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    Dr Paul Brown

    Dr Paul Brown, Global Project Leader, Hoffmann-La Roche

  • Preventing structural joint damage in rheumatoid arthritis patients
  • Involvement of matrix metalloproteases in rheumatoid arthritis
  • Discovery and development of TROCADE, a Collagenase Selective Inhibitor
  • Clinical and regulatory challenges
  • Outlook for RA disease management
  • 11:00 Morning Coffee

    11:20 DEVELOPING DISEASE MODIFYING AGENTS FOR THE TREATMENT OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS

    Dr Kim Tan

    Dr Kim Tan, Managing Director, KS Biomedix

  • Specialising in arthritis and antibodies
  • Therapeutic approaches to normalise the biochemistry of the osteoarthritis and rheumatoid arthritis disease environments
  • Clinical development updates for CB-2431 in osteoarthritis and CBF-BS2 in rheumatoid arthritis
  • 12:00 TURNING HUMAN ANTIBODIES INTO HUMAN DRUGS

    Dr Kevin Johnson

    Dr Kevin Johnson, Research Director, Cambridge Antibody Technology

  • Human monoclonal antibody technology
  • Construction of D2E7, a human antibody targeted against TNF alpha
  • Antagonists of TGF beta and IL12
  • Industrialising the process: High throughput target identification and lead optimisation
  • 12:40 Lunch

    13:40 DISCOVERING NEW DRUGS FOR TREATING IMMUNOLOGICAL DISEASES

    Dr Joachim Kempeni

    Dr Joachim Kempeni, Head, Clinical Oncology / Immunology, BASF Bioresearch

  • Expanding its arthritis RandD programme
  • Working towards the discovery of novel anti inflammatory compounds that block production of certain cytokines
  • Working on novel immunosuppressive agents that block activation of immune cells
  • Taking its first product candidate into clinical trials for the treatment of RA
  • Benefits for the patient
  • Pharmacoeconomical implications of novel arthritis treatment
  • 14:20 TREATING RHEUMATOID ARTHRITIS

    Dr Thomas F Schaible

    Dr Thomas F Schaible, Senior Director, Immunology Medical Affairs, Centocor

  • Finding treatment for rheumatoid arthritis
  • REMICADE™: mechanism of action
  • Safety and efficacy of REMICADE™
  • Significant reduction of RA symptoms
  • Sustaining long-term clinical benefits for patients suffering from rheumatoid arthritis
  • Anticipating the future of treating rheumatoid arthritis
  • 15:00 ISSUES FOR CHRONIC TREATMENT WITH ANTIBODY THERAPIES

    Dr Ursula Ney

    Dr Ursula Ney, Director of Development, Celltech Chiroscience

  • Safety, efficacy and pk of antibodies for chronic therapy
  • Consequence of immune response generation
  • Use of engineered human antibodies for chronic use: repeat administration with CDP571, humanised anti-TNF
  • Commercial issues for chronic antibody use: supply, scale of manufacture, cost of goods, pricing
  • Microbial expression of antibody fragments for large scale production
  • Clinical Evaluation of CDP870, a microbially expressed Fab’ conjugate
  • 15:40 Afternoon Tea

    16:00 WORKING WITH POTENT INHIBITORS OF TNF-ALPHA

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer, Celgene

  • Identifying the immunotherapeutic activities of Immunomodulating Drugs™, (IMiDs™,)
  • ImiDs™, a novel class of small molecule pharmaceuticals
  • Mechanism of action of IMiDs™,
  • Distinct and highly specific immunotherapeutic responses by derivatives of thalidomide
  • Thalidomide derivatives with a greatly reduced toxicity profile
  • Benefits for the patient
  • 16:30 ASSESSING EFFICACY AND SAFETY OF TACROLIMUS IN RHEUMATOID ARTHRITIS PATIENTS

    Dr Ira D Lawrence

    Dr Ira D Lawrence, Vice President, Research and Development, Fujisawa

  • A potential role for tacrolimus in the treatment of rheumatoid arthritis
  • Taking tacrolimus into clinical trials for the treatment of rheumatoid arthritis
  • Assessing the efficacy and safety of tacrolimus in rheumatoid arthritis patients
  • Choosing RA patients who have demonstrated resistance to or intolerance of disease modifying anti rheumatic drugs
  • Demonstrating significant clinical and laboratory improvements
  • Benefits for the patient
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Informal Networking Drinks Reception for Speakers and Delegates

    8:30 Registration and Coffee

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Barry Bresnihan

    Prof Barry Bresnihan, Professor of Rheumatology, St. Vincent’s University Hospital Dublin

    9:10 FINDING TREATMENT FOR RHEUMATOID ARTHRITIS WHICH ALLOWS GREATER EASE AND FLEXIBILITY FOR THE PATIENT

    Dr George Schreiner

    Dr George Schreiner, Vice President, Cardiorenal Research, Scios

  • P38-kinase, a key factor in the intracellular pathway that stimulates the synthesis of TNF alpha
  • The role of p38-kinase in rheumatoid arthritis
  • Identifying lead compounds which inhibit p38-kinase
  • Optimising small molecule compounds for clinical development
  • Advantages of small molecule p38-kinase inhibitor
  • Preparing for taking its lead p38-kinase inhibitor into clinical trials
  • 9:40 POTENTIAL USE OF PENTOSTATIN FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    Dr Rajesh C Shrotriya

    Dr Rajesh C Shrotriya, Executive Vice President and Chief Scientific Officer, SuperGen

  • Developing pentostatin
  • Pentostatin’s involvement in rheumatoid arthritis
  • Mechanism of action of pentostatin
  • Advantages of pentostatin
  • Benefits for the patient
  • 10:20 USING A WHITE BLOOD CELL FORMULATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

    Dr Nigel Smart

    Dr Nigel Smart, President, Inflammatics

  • Developing LeukoVAX™
  • Mechanism of action of LeukoVAX™
  • Taking LeukoVax™ into clinical trials for the treatment of RA
  • Safer and more effective therapy to treat long-term chronic conditions
  • Advantages of LeukoVax™
  • Meeting patients needs
  • 11:00 Morning Coffee

    11:20 APPLYING ITS IMMUNOLOGICAL EXPERTISE

    Dr Steven Gillis

    Dr Steven Gillis, Chairman and Chief Executive Officer, Corixa

  • The involvement of MHC in autoimmune disease
  • Two platform technologies for treating autoimmune disease
  • AnervaX.RA DR4/1 peptide vaccine for rheumatoid arthritis Mechanism of action Animal models Safety and efficacy in clinical trials
  • AnergiX.RA DR4-HCgp39 complex for rheumatoid arthritis Mechanism of action Animal models Safety and efficacy in clinical trials Recent developments with recombinant AnergiX complexes
  • Stopping further destruction of tissue caused by harmful T-cells
  • Potential benefits of its RA vaccine
  • 12:00 STRATEGIES FOR APPLYING INHIBITORS OF COMPLEMENT ACTIVATION IN ARTHRITIS THERAPY

    Dr Richard Smith

    Dr Richard Smith, Chief Scientific Officer, AdproTech

  • The role of complement activation in the pathology and development of rheumatoid arthritis
  • Inhibitors of complement activation: preclinical and clinical experience of a new drug class
  • Development of complement regulators from bacterial expression systems
  • Boosting a minimized protein pharmacophore: the need for an intrinsic mechanism of action
  • Development of a generally applicable membrane-targeting technology
  • Activity of a membrane-targeted complement inhibitor in animal models of arthritis
  • 12:40 Lunch

    14:00 DEVELOPING THE NEXT GENERATION OF ANTI-INFLAMMATORY DRUGS

    Dr Joseph Rudick, President and Chief Executive Officer, Atlantic Pharmaceuticals

    Dr Joseph Rudick, President and Chief Executive Officer, Atlantic Pharmaceuticals, Dr Sumner Burstein, Professor, Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School

  • Developing a diverse portfolio of independent product candidates licensed from a variety of sources
  • Research leading to CT-3 (ajulemic acid) as a candidate molecule for the treatment of pain and inflammation
  • Experimental evidence for the lack of toxicity in the gastrointestinal and central nervous systems
  • Possible unique mechanisms involved in the anti inflammatory effects of CT-3
  • The existence of a putative endogenous ligand for the CT-3 receptor
  • A potential clinical role for CT-3 in rheumatoid arthritis
  • 14:40 DEVELOPING A NON-DRUG TREATMENT ALTERNATIVE FOR PATIENTS WITH RHEUMATOID ARTHRITIS

    Dr Jay D Kranzler

    Dr Jay D Kranzler, Chief Executive Officer, Cypress Bioscience

  • Generating a non-drug alternative for patients with moderate to severe RA
  • Developing Prosorba®
  • Mechanism of action of Prosorba®
  • Safety and efficacy of Prosorba®
  • Benefits for the patient
  • Anticipation the future of non-drug treatment alternatives for RA patients
  • 15:20 Afternoon Tea

    15:40 ELASTOVISCOUS HYLAN BIOPOLYMER FOR OSTEOARTHRITIS OF THE KNEE

    Dr Endre Balazs

    Dr Endre Balazs, CEO and Chief Scientific Officer, Biomatrix

  • Making proprietary biological polymers called hylans for therapeutic uses
  • Treating osteoarthritis with Synvisc
  • Developing Synvisc
  • Mechanism of action of Synvisc
  • Benefits for the patient
  • Pharmacoeconomic aspects of Synvisc
  • 16:20 DEVELOPING AN ELISA FOR THE DETECTION ON ANTI-NUCLEAR ANTIBODIES

    Dr Jim Weston

    Dr Jim Weston, General Manager, Cogent Diagnostics

  • Measuring the presence of anti-nuclear antibodies associated with arthritic diseases
  • Developing an ANA-ELISA
  • Screening large numbers of samples in an automated fashion
  • Replacing the immunofluorescence screening method
  • Providing an accurate, reliable test result for physicians and their patients
  • Pharmacoeconomical implications of early accurate diagnosis
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Partnerships between the Pharmaceutical Industry and Biotech Companies:
    Workshop

    Partnerships between the Pharmaceutical Industry and Biotech Companies:

    The Hatton, at etc. venues
    26th January 2000
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.